Thermo Fisher Scientific Inc

The materials sector has been among the worst hit in the market. Is now the time to invest for long-term growth?

On February 24, Microsoft announced that it will acquire Xamarin, a mobile app platform provider. Financial details of the deal were not disclosed.

In Q3 2020, billionaire investor Leon Cooperman’s top five holdings were Fiserv, Mr. Cooper Group, Alphabet, Cigna, and Trinity Industries.

The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.

Stryker (SYK) registered strong 3Q16 earnings on October 27, 2016. The company’s reported earnings exceeded analysts’ estimates.

Boston Scientific (BSX) was trading at $27.9 on June 29, 2017.

Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.

Cost transformation for growth (or CTG) is Stryker’s program that focuses on driving leveraged growth by structural cost optimization.

In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.

Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.

Abbott stock has been gaining momentum recently, and its valuation has improved.

Thermo Fisher Scientific (TMO) operates in four business segments.

Thermo Fisher Scientific (TMO) will announce its 4Q17 and fiscal 2017 results on January 31, 2018. It has launched some innovative products and entered into strategic collaborations and partnerships.

The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17.

In December 2017, Thermo Fisher Scientific (TMO) expanded its partnership with Genome Diagnostics (or GenDx), a Netherlands-based firm offering molecular diagnostics solutions.

Overview BD (BDX) has registered strong operating margin expansion in recent years. Its margin improved by 100 basis points in fiscal 2015 and 200 basis points in fiscal 2016. In fiscal 2017, BD’s margin expanded by ~180 basis points. In 4Q17, BD’s operating margin grew ~14.6% YoY (year-over-year), limited by 700 basis points due to the divestiture of BD’s […]

On September 7, 2017, BAX stock closed at $62.84 per share. It has a 50-day moving average of $61.15 and a 200-day moving average of $57.14.

Becton Dickinson’s (BDX) emerging markets registered a strong double-digit growth of 10.9% in 3Q17.

On June 29, 2017, Thermo Fisher Scientific (TMO) announced the addition of three new products to its semiconductor failure analysis workflows portfolio.

Zimmer Biomet Holdings (ZBH) was trading at $118.40 on May 30, 2017. It has a 50-day moving average of $119.70 and a 200-day moving average of $114.20.

Thermo Fisher Scientific expects to deploy 60%–75% of its capital toward M&As (mergers and acquisitions).

Thermo Fisher Scientific (TMO) has always focused on innovation as a key growth strategy.

Thermo Fisher Scientific (TMO) has a presence around the globe, but around 80% of its revenues are generated from developed markets.

In 1Q17, Bio-Rad Laboratories’ (BIO) Life Science segment reported revenues of ~$174.3 million, which represents a YoY rise of ~5.1%.

On March 13, 2017, Bio-Rad Laboratories (BIO) provided a long-term, currency-neutral revenue growth target of around 3%–5%.

Becton, Dickinson and Company (BDX) recently launched BD Barricor and BD Ultra Touch Push Button under its Pre-Analytical Systems division.

Thermo Fisher Scientific (TMO) completed the acquisition of FEI Company on September 19, 2016.

Cost transformation growth is one of Stryker’s key strategies for driving growth. The company has come a long way from its decentralized structure prior to 2010.

Thermo Fisher Scientific reported ~$4.5 billion in revenues in 2Q16, representing YoY (year-over-year) growth of ~6%.

The PPI system has helped nourish strong top-line growth across Thermo Fisher’s businesses while boosting margins.

Thermo Fisher has a presence in more than 50 countries. It generates ~19% of its revenues from emerging markets and the rest from developed markets.

Varian Medical Systems’ next big technology innovation will be high-definition radiotherapy, which is an intelligent treatment delivery system that aims to achieve 100% radiation exposure for the tumor.

Abbott Laboratories’ Nutritional Products segment is the company’s leading segment, growing at a fast pace, with rapidly increasing margins and revenues.

To better position itself amid the changing medical device environment, Becton Dickinson has come to focus on restructuring and business model evolution.

Thermo Fisher Scientific is a global company, but the majority of its revenues are generated from the developed markets. The US is its largest market, generating ~48% of the company’s total revenues.

Thermo Fisher Scientific (TMO) has made a number of acquisitions over the years, resulting in the expansion of the company’s product portfolio with the inclusion of a number of premium brands.

Thermo Fisher Scientific’s Analytical Instruments segment earned revenues of ~$3.3 billion in 2014, representing organic growth of around 4%.

A leading provider of diagnostic products and services, Thermo Fisher Scientific (TMO) has witnessed strong recurring revenues and high margins in the Specialty Diagnostics Segment over the years.

Thermo Fisher Scientific’s Life Sciences Solutions segment earned revenues of ~$4.2 billion in 2014, representing organic growth of around 4%.

Thermo Fisher Scientific’s Laboratory Products and Services segment earned revenues of approximately $6.6 billion in 2014, representing organic growth of around 5%.

Thermo Fisher Scientific (TMO) is one of the leading medical technology companies in the world, providing a broad portfolio of laboratory equipment and services.

Stryker is a leading medical technology company and subject to big challenges impacting the medical technology industry, both systematic and unsystematic.

Medical devices are classified as per the level of control required by the Food, Drug, and Cosmetic Act (or FD&C Act).

Third Point started a new 2.83% position in gas pipeline operator Williams Companies, Inc.